What age-based CA125 thresholds reveal about winning adoption in NHS cancer pathways
NICE Redefines Ovarian Cancer Testing
More women with ovarian cancer in England could be diagnosed earlier and more accurately under ambitious draft guidance published this month by the National Institute for Health and Care Excellence (NICE). The update proposes replacing the long-standing, one-size-fits-all CA125 blood test threshold with personalised, age-based criteria a shift that clinicians and policy analysts say could reshape how cancer is detected in primary care.
Currently, UK practice relies on a single rule: a CA125 blood level of 35 IU/ml or above prompts further investigation, regardless of a woman’s age. But growing evidence suggests this static cut-off is blunt. It can miss cancers in older women, whose disease may not trigger large CA125 rises, while driving unnecessary scans and anxiety in younger women, where CA125 is less specific and more likely to be elevated for benign reasons.
Around 1 in 50 women will develop ovarian cancer in their lifetime, with around 7,000 women diagnosed each year in the UK. The disease is often caught late because symptoms such as bloating, abdominal pain and feeling full quickly can be vague and overlap with other conditions.
A draft update to our guideline on suspected cancer proposes new thresholds for the CA125 blood test that reflect how ovarian cancer risk changes as women get older.
A CA125 blood test measures levels of a protein in blood, which are often elevated in cases of ovarian cancer, and can be used for monitoring existing cancer or guiding further investigation.
Currently, all women are referred for further investigation if their CA125 level reaches 35 IU/ml or above, regardless of age. This fixed threshold can miss cancers in older women while triggering unnecessary investigations in younger women.
The guideline also recognises that for women under 40, CA125 testing alone is not sufficiently accurate to guide decisions. For this group, GPs should consider arranging an ultrasound scan directly for those with persistent symptoms.
The committee’s proposed recommendations will ensure more personalised, targeted testing, so women at greatest risk of ovarian cancer are identified and referred sooner.
This tailored approach will mean GPs can make more informed decisions about which patients need urgent investigation, while reducing unnecessary ultrasound scans, freeing up NHS resources.
These updates will ensure that our guideline reflects the latest evidence and will help improve the detection of cancer and ensure those who need it get swift treatment.
Eric Power, deputy director, Centre for Guidelines
Why age matters in ovarian cancer testing
Ovarian cancer is often described as a “silent killer”. Symptoms such as persistent bloating, abdominal discomfort and feeling full quickly are vague, common, and easily attributed to non-cancer conditions. Around one in 50 women will develop ovarian cancer during their lifetime, with approximately 7,000 new cases diagnosed in the UK each year. Yet most diagnoses still occur late, when treatment options are fewer and survival is poor.
NICE’s draft guidance makes age a central part of interpreting CA125 results, reflecting two realities: ovarian cancer risk rises steeply with age, and the performance of CA125 varies across the lifespan. In effect, the same blood result does not carry the same meaning for a 35-year-old as it does for a 75-year-old.
What the draft guidance proposes
For women under 40, NICE advises that CA125 alone is not sufficiently accurate to guide decisions. Instead, GPs should consider arranging a pelvic ultrasound directly for those with persistent or concerning symptoms, rather than relying on a reassuring blood result to close down further investigation.
For people aged 40 and over, the draft replaces the universal 35 IU/ml trigger with age-stratified CA125 thresholds that guide referral for ultrasound. In practical terms, this means lower CA125 levels in older age groups may now prompt investigation, while higher thresholds apply in younger adults where cancer risk is lower.
The implication is significant: a CA125 result that might previously have been labelled “normal” in an older patient could now trigger an urgent diagnostic pathway potentially catching cancers earlier in a group where delayed diagnosis has long been the norm.
Expert voices and clinical rationale
NICE says the change is about targeting risk, not just ticking boxes. Eric Power, deputy director of the Centre for Guidelines, explained that the proposed recommendations aim to ensure “more personalised, targeted testing, so women at greatest risk of ovarian cancer are identified and referred sooner.” He added that the approach should help GPs make better-informed decisions while reducing unnecessary ultrasound scans and easing pressure on NHS diagnostic services.
Front-line clinicians have broadly welcomed the logic. Professor Azeem Majeed, head of primary care and public health at Imperial College London, told Pulse Today that age-based thresholds give GPs cleaner risk signals, helping them avoid over-investigation of younger women while improving vigilance in older patients, where the stakes are higher.
NICE IS CHANGING https://odelletechnology.com/how-to-secure-nice-approval-in-the-nhs-scientific-and-health-economic-guide-for-health-tech/
Additional red flags and evidence gaps
The draft guidance goes beyond CA125. It introduces a new red-flag criterion for people aged 60 and over with unexplained weight loss of more than 5% over six months, recommending urgent investigation or referral via the suspected cancer pathway.
NICE also takes a notably cautious stance on unexpected bleeding in women using hormone replacement therapy (HRT). With HRT prescriptions rising in England, the guideline acknowledges uncertainty about when such bleeding should trigger investigation for endometrial cancer. Rather than issuing rigid rules, NICE calls for further research, signalling a willingness to be transparent about evidence gaps rather than over-specifying practice.
What’s at stake
By anchoring CA125 interpretation to age, NICE is trying to address two long-standing problems in ovarian cancer care: late-stage diagnosis and diagnostic inefficiency. Older women have historically been under-triaged by fixed thresholds, while younger women have faced unnecessary referrals, scans and anxiety because of CA125’s low specificity in that group.
The draft guideline is open to public consultation until 2 February 2026, with final recommendations expected later in the spring. If adopted, it would represent one of the most significant changes to primary care cancer testing guidance in years.
Behind the headlines: what comes next
Implementation will matter. Clinical pathways and GP decision-support tools will need updating to reflect age-specific CA125 thresholds. Ultrasound demand may shift, with more proactive imaging in older cohorts and more selective use in younger patients. Further research will also be crucial—particularly on combined strategies, such as simultaneous CA125 testing and ultrasound, and on how age-based risk models perform in real-world practice.
Taken together, the draft guidance signals a broader change in thinking. Diagnostics are moving away from blanket cut-offs towards smarter, risk-aligned care, where age, symptoms and clinical judgement are integrated to improve early cancer detection without overwhelming patients or the health system.
What is CA125 and what does the test actually measure?
CA125 (cancer antigen 125) is a glycoprotein (MUC16) shed from the surface of certain epithelial cells, including ovarian cancer cells. It can be detected in blood and has been used for decades as a tumour-associated biomarker, particularly in ovarian cancer.
However, CA125 is not cancer-specific. Levels can rise due to:
- Benign gynaecological conditions (e.g. endometriosis, fibroids)
- Menstruation
- Pregnancy
- Liver disease
- Inflammation of the peritoneum or pleura
This biological non-specificity is central to why CA125 performs differently across age groups.
Why has the CA125 test historically used a single threshold of 35 IU/mL?
The 35 IU/mL cut-off was originally derived from early population studies aimed at balancing sensitivity and specificity in mixed cohorts. It was never designed to be age-calibrated; rather, it was a pragmatic compromise adopted for simplicity in clinical practice. Over time, that simplicity became embedded in pathways—even as evidence accumulated showing that baseline CA125 distributions shift with age and physiology.
Why does CA125 perform differently in younger versus older women?
The test’s positive predictive value (PPV) and negative predictive value (NPV) depend heavily on pre-test probability, which rises steeply with age.
- In younger women, ovarian cancer is rare. Even moderately raised CA125 levels are far more likely to reflect benign conditions, producing false positives.
- In older women, cancer prevalence is higher, but CA125 rises can be subtle, meaning a fixed threshold may fail to trigger investigation, producing false negatives.
NICE’s change explicitly recognises that a biomarker’s meaning is context-dependent, not absolute.
What scientific evidence supports age-based CA125 thresholds?
The draft guideline draws on:
- Large UK primary care datasets linking CA125 levels, age, symptoms and cancer outcomes
- Modelling studies showing that age-adjusted thresholds improve discrimination
- Evidence that risk-based triage improves referral accuracy without increasing overall investigation burden
Importantly, NICE did not require CA125 to become “perfect”; instead, it asked whether interpretation could be made smarter.
Why does NICE say CA125 alone is not accurate in women under 40?
In women under 40:
- Ovarian cancer incidence is very low
- CA125 elevations are frequently driven by benign or physiological causes
- A “normal” CA125 can falsely reassure when symptoms persist
NICE therefore concludes that symptoms must take precedence over biomarkers in this group, recommending direct ultrasound when symptoms are ongoing—reflecting a precautionary, patient-safety-oriented stance.
How did NICE actually make this decision?
The process followed NICE’s standard guideline development methodology, involving:
- Systematic evidence review (diagnostic accuracy, outcomes, harms)
- Risk modelling rather than simple sensitivity/specificity comparisons
- Clinical committee deliberation, including GP and specialist input
- Health system impact assessment, including ultrasound capacity
- Public consultation, allowing external challenge and refinement
Crucially, NICE assessed decision impact, not just test performance.
Why didn’t NICE recommend a new test instead of adjusting CA125?
NICE generally prioritises:
- Optimising existing tools before introducing new ones
- Changes that can be implemented immediately at national scale
- Interventions that improve outcomes without increasing cost or complexity
Age-based interpretation of CA125 meets all three criteria and avoids the delays inherent in adopting new diagnostics.
Why is ultrasound now emphasised differently in the pathway?
Ultrasound is:
- More specific for ovarian pathology
- Less influenced by systemic or benign inflammatory processes
- Already embedded in NHS diagnostic infrastructure
By adjusting who gets referred for ultrasound, NICE is effectively rebalancing diagnostic effort, not increasing it—an important point for capacity-constrained systems.
Why did NICE include weight loss and HRT-related bleeding in the same update?
Because NICE guidelines are pathway-based, not test-based.
- Unexplained weight loss in older adults is a non-specific but high-risk systemic signal
- HRT-related bleeding represents a known evidence gap, particularly for endometrial cancer
Including both reflects NICE’s broader role: harmonising symptom signals, tests and referral logic into coherent decision pathways.
Glossary of Terms: NICE, CA125 and Cancer Diagnostics
CA125 (Cancer Antigen 125)
A tumour-associated glycoprotein (also known as MUC16) measurable in blood. CA125 is commonly used in the investigation and monitoring of ovarian cancer but is not cancer-specific and can be elevated in many benign conditions.
Age-Based Thresholds
Diagnostic cut-off values that vary according to patient age, reflecting changes in disease prevalence and biomarker performance across the lifespan. NICE proposes age-based CA125 thresholds to improve referral accuracy for ovarian cancer.
Suspected Cancer Pathway
A formal NHS referral route enabling urgent investigation of patients with symptoms or test results suggestive of cancer, typically aiming for specialist assessment within defined timeframes.
Pre-Test Probability
The estimated likelihood that a patient has a disease before a diagnostic test result is known. Pre-test probability strongly influences how test results should be interpreted and is central to NICE’s move toward risk-adjusted diagnostics.
Positive Predictive Value (PPV)
The probability that a patient actually has the disease given a positive test result. PPV increases as disease prevalence rises, which is why CA125 performs differently in older versus younger women.
Negative Predictive Value (NPV)
The probability that a patient does not have the disease given a negative test result. In low-prevalence groups, a negative test may still fail to exclude disease if sensitivity is limited.
False Positive
A test result that suggests disease when none is present. In ovarian cancer testing, false positives can lead to unnecessary imaging, anxiety and further investigations.
False Negative
A test result that fails to detect disease when it is present. Fixed CA125 thresholds can produce false negatives in older women if cancer-associated rises are modest.
Risk-Adjusted Testing
An approach to diagnostics in which test interpretation is modified by patient-specific factors such as age, symptoms and baseline risk, rather than relying on a single universal cut-off.
Diagnostic Yield
The proportion of investigations that result in a meaningful diagnosis, such as confirmed cancer. NICE aims to increase diagnostic yield while avoiding unnecessary testing.
Ultrasound (Pelvic Ultrasound)
An imaging modality used to visualise the ovaries and surrounding structures. Ultrasound is more specific for ovarian pathology than CA125 alone and is a key component of NICE’s revised diagnostic pathway.
Persistent Symptoms
Symptoms that continue over time despite initial assessment or reassurance. NICE places greater weight on symptom persistence, particularly in younger women where biomarkers may be misleading.
Health System Capacity
The availability of NHS resources—such as imaging services, specialist clinics and workforce—to deliver diagnostic care. NICE considers capacity explicitly when updating diagnostic pathways.
Guideline Development Committee
A multidisciplinary group convened by NICE to review evidence, model outcomes and make recommendations. Committees typically include GPs, specialists, methodologists and patient representatives.
Evidence Gap
An area where available data are insufficient to support a firm recommendation. NICE may call for further research rather than issuing prescriptive guidance, as seen with HRT-related bleeding and endometrial cancer risk.
Pathway-Based Decision Making
An approach that evaluates how tests, symptoms and referrals interact across the entire patient journey, rather than assessing each diagnostic element in isolation.
Risk Stratification
The process of grouping patients by estimated disease risk to guide investigation and management. Age-based CA125 thresholds are an example of formal risk stratification.
Diagnostic Efficiency
The ability of a healthcare system to identify disease accurately and promptly while minimising unnecessary tests, referrals and costs.
Clinical Utility
The extent to which a diagnostic test improves real-world clinical decisions and outcomes, not just analytical accuracy. NICE prioritises clinical utility in guideline updates.
References
National Institute for Health and Care Excellence (NICE) (2026) New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier. NICE News. Available at: https://www.nice.org.uk/news/articles/new-age-based-blood-test-thresholds-recommended-by-nice-will-help-gps-catch-ovarian-cancer-earlier
National Institute for Health and Care Excellence (NICE) (2026) Suspected cancer: recognition and referral – draft update (GID-NG10443). London: NICE. Available at: https://www.nice.org.uk/guidance/GID-NG10443/documents .
Health Professional Academy (2026) NICE recommends new blood test thresholds to help GPs detect ovarian cancer earlier. Available at: https://www.healthprofessionalacademy.co.uk/news/nice-recommends-new-blood-test-thresholds-to-help-gps-detect-ovarian-cancer-earlier
Pulse Today (2026) NICE proposes new age thresholds for ovarian cancer referral following a blood test. Available at: https://www.pulsetoday.co.uk/news/clinical-areas/womens-health-gynaecology-obstetrics/nice-proposes-new-age-thresholds-for-ovarian-cancer-referral-following-blood-test/
Power, E. (2026). Statement quoted in: New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier. National Institute for Health and Care Excellence (NICE). Available at: https://www.nice.org.uk/news/articles/new-age-based-blood-test-thresholds-recommended-by-nice-will-help-gps-catch-ovarian-cancer-earlier
Majeed, A. (2026) Commentary quoted in: NICE proposes new age thresholds for ovarian cancer referral following blood test. Pulse Today. Available at: https://www.pulsetoday.co.uk/news/clinical-areas/womens-health-gynaecology-obstetrics/nice-proposes-new-age-thresholds-for-ovarian-cancer-referral-following-blood-test/